2 weeks Ago By ABMN Staff
Vanguard Group Inc. boosted its position in Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN – Free Report ) by 0.
4% during the 4th quarter, Holdings Channel.com reports. The fund owned 6,150,759 shares of the specialty pharmaceutical company’s stock after buying an additional 22,852 shares during the quarter.
Vanguard Group Inc. owned about 0.11% of Supernus Pharmaceuticals worth $222,411,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 5.3% in the 3rd quarter.
Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after purchasing an additional 74,438 shares during the last quarter. American Century Companies Inc. lifted its holdings in Supernus Pharmaceuticals by 9.
2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock valued at $41,248,000 after buying an additional 95,777 shares during the period.
Charles Schwab Investment Management Inc. boosted its stake in Supernus Pharmaceuticals by 5.8% in the fourth quarter.
Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock valued at $27,242,000 after acquiring an additional 40,968 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Supernus Pharmaceuticals by 7.
3% during the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock worth $14,449,000 after acquiring an additional 27,134 shares during the period. Finally, Principal Financial Group Inc.
raised its position in shares of Supernus Pharmaceuticals by 4.0% during the 4th quarter. Principal Financial Group Inc.
now owns 296,732 shares of the specialty pharmaceutical company’s stock valued at $10,730,000 after acquiring an additional 11,321 shares during the last quarter. Insider Buying and Selling In related news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.
15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.
95. This trade represents a 10.56 % decrease in their ownership of the stock.
The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink . Also, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th.
The stock was sold at an average price of $39.62, for a total transaction of $27,734.00.
Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. The trade was a 6.
45 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last quarter, insiders have sold 11,104 shares of company stock valued at $440,263.
9.30% of the stock is owned by company insiders. Wall Street Analyst Weigh In View Our Latest Stock Analysis on Supernus Pharmaceuticals Supernus Pharmaceuticals Stock Up 0.
8 % Shares of NASDAQ SUPN opened at $32.74 on Friday. Supernus Pharmaceuticals, Inc.
has a twelve month low of $25.53 and a twelve month high of $40.28.
The stock has a market cap of $1.83 billion, a price-to-earnings ratio of 30.60 and a beta of 0.
84. The company’s fifty day moving average is $34.57 and its 200-day moving average is $35.
06. Supernus Pharmaceuticals Company Profile ( Free Report ) Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Featured Stories Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN – Free Report ).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
